MBX Capital

Founded -

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 2
Average round size
info
The average size of a deal this fund participated in
$11M
Portfolio companies 3
Lead investments 1
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Drug Discovery
  • Pharmaceuticals
  • Medical Device

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Contraline

Biotechnology
Drug Discovery
Health Care
Medical Device
Pharmaceuticals
$6M31 Oct 2020 Virginia, United States

Koneksa Health

Analytics
Big Data
Health Care
$16M28 Sep 2020 New York, New York, United States
News
Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

– Contraline, Inc. has closed $10.7m in its Series A financing.
– The financing round was led by MBX Capital, a venture capital firm that invests in early-stage healthcare and life sciences companies.
– The infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.
– The ADAM hydrogel is injected into the vas deferens through a quick and minimally invasive outpatient procedure, where it’s designed to block the flow of sperm.
– This trial on ADAM is believed to be the first clinical trial on a non-hormonal male contraceptive device in over 20 years.

Maternal Health Platform Mae Launches with $1.3M

– Digital health platform, Mae, announced its $1.3M pre-seed funding round led by SteelSky Ventures.
– Other investors in this pre-seed round include Avestria Ventures, MBX Capital, Rhia Ventures.
– This list of investors represents participation from three of the most prominent venture capital funds in the women’s health space, underscoring a commitment to and belief in Mae’s innovative delivery model and its potential to drive health equity and positive outcomes for Black expectant mothers and their babies.
– Mae was founded by CEO Maya Hardigan, following 15-years in digital health product innovation, most recently at Pfizer.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent MBX Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: